Skip to content

Michael Jeltsch

  • Dr.
  • Group leader & Academy Research Fellow
  • Helsingin yliopisto - University of Helsinki
  • 32

    h-index

    Impact measure calculated by Scopus using these publications and citation counts.
  • 9139

    Citations

    Number of citations received by these publications in Scopus.

Research Interests

(Lymph)angiogenesis Protein production and purification Antibody technologies

Followers (8)

Explore network

Following (4)

About

2013 Group leader in the Translational Cancer Biology Program, University of Helsinki, Finland 2011 Habilitation (Proteinchemie), University of Helsinki, Finland 2002 PhD (Biochemistry), University of Helsinki, Finland 1997 MSc (Biochemistry), University of Helsinki, Finland 1992 BSc ("Vordiplom", Biochemie/Molekularbiologie), University of Hamburg, Germany 1989 Allgemeine Hochschulreife, Gymnasium An der Stenner, Iserlohn, Germany July 28, 1969 Born in Hemer/NW, Germany

Publications

Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis

  • Anisimov A
  • Tvorogov D
  • Alitalo A
  • Leppänen V
  • An Y
  • Han E
  • Orsenigo F
  • Gaál E
  • Holopainen T
  • Koh Y
  • Tammela T
  • Korpisalo P
  • Keskitalo S
  • Jeltsch M
  • Ylä-Herttuala S
  • Dejana E
  • Koh G
  • Choi C
  • Saharinen P
  • Alitalo K
Circulation (2013)
  • --

    Readers

    Readers not available. This publication is not currently accessible in the Mendeley catalog.
Full text

Structural determinants of growth factor binding and specificity by VEGF receptor 2

  • Leppänen V
  • Prota A
  • Jeltsch M
  • Anisimov A
  • Kalkkinen N
  • Strandin T
  • Lankinen H
  • Goldman A
  • Ballmer-Hofer K
  • Alitalo K
Proceedings of the National Academy of Sciences of the United States of America (2010)
  • --

    Readers

    Readers not available. This publication is not currently accessible in the Mendeley catalog.
Full text

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes

  • Saaristo A
  • Veikkola T
  • Enholm B
  • Hytönen M
  • Arola J
  • Pajusola K
  • Turunen P
  • Jeltsch M
  • Karkkainen M
  • Kerjaschki D
  • Bueler H
  • Ylä-Herttuala S
  • Alitalo K
FASEB Journal (2002)
  • --

    Readers

    Readers not available. This publication is not currently accessible in the Mendeley catalog.
Full text

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

  • Veikkola T
  • Jussila L
  • Makinen T
  • Karpanen T
  • Jeltsch M
  • Petrova T
  • Kubo H
  • Thurston G
  • McDonald D
  • Achen M
  • Stacker S
  • Alitalo K
EMBO Journal (2001)
  • --

    Readers

    Readers not available. This publication is not currently accessible in the Mendeley catalog.
Full text

VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane

  • Oh S
  • Jeltsch M
  • Birkenhäger R
  • McCarthy J
  • Weich H
  • Christ B
  • Alitalo K
  • Wilting J
Developmental Biology (1997)
  • --

    Readers

    Readers not available. This publication is not currently accessible in the Mendeley catalog.
Full text

Professional experience

Group leader & Academy Research Fellow

Helsingin yliopisto - University of Helsinki

September 2013

Postdoctoral Fellow

Wihuri Research Institute

January 2013 - August 2013 (7 months)

graduate student, postgraduate student, postdoc

Molecular/Cancer Biology Lab, University of Helsinki

May 1996 - August 2013 (17 years)

Researcher

Circadian Technologies via Vegenics Ltd. via Licentia Ltd.

February 2007 - December 2011 (5 years)

Researcher

Lymphatix Ltd. (now Ark Therapeutics) via Licentia Ltd.

April 2006 - January 2007 (9 months)

Studentische Hilfskraft

Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg

August 1993 - July 1994 (a year)